CD19 and leukemia: Regarding clinical trials, Anti-CD33 CAR NK cells for acute myeloid leukemia (NCT02944162, PMID: 28054442), Allogeneic anti-CD19 CAR NK cells for CD19 + Leukemia (NCT02892695, PMID: 28054442), ROBO1 CAR NK cells for Solid tumor expressing ROBO1 (NCT03940820) and allogeneic anti-MUC1 CAR pNK cells for MUC1-positive solid tumor (NCT02839954) have been performed.